<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr J</journal-id><journal-id journal-id-type="iso-abbrev">Nutr J</journal-id><journal-title-group><journal-title>Nutrition Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2891</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24192015</article-id><article-id pub-id-type="pmc">4176102</article-id><article-id pub-id-type="publisher-id">1475-2891-12-142</article-id><article-id pub-id-type="doi">10.1186/1475-2891-12-142</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effects of coenzyme Q10 supplementation (300&#x000a0;mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Lee</surname><given-names>Bor-Jen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>borjen@vghtc.gov.tw</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Tseng</surname><given-names>Yu-Fen</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>baby000020022002@hotmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Yen</surname><given-names>Chi-Hua</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>cshy352@csh.org.tw</email></contrib><contrib contrib-type="author" corresp="yes" id="A4"><name><surname>Lin</surname><given-names>Ping-Ting</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I6">6</xref><email>apt810@csmu.edu.tw</email></contrib></contrib-group><aff id="I1"><label>1</label>The Intensive Care Unit, Taichung Veterans General Hospital, Taichung 40705, Taiwan</aff><aff id="I2"><label>2</label>School of Nutrition, Chung Shan Medical University, Taichung 40201, Taiwan</aff><aff id="I3"><label>3</label>Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan</aff><aff id="I4"><label>4</label>School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan</aff><aff id="I5"><label>5</label>Center for Education and Research on Geriatrics and Gerontology, Chung Shan Medical University, Taichung 40201, Taiwan</aff><aff id="I6"><label>6</label>Department of Nutrition, Chung Shan Medical University Hospital, Taichung 40201, Taiwan</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2013</year></pub-date><volume>12</volume><fpage>142</fpage><lpage>142</lpage><history><date date-type="received"><day>12</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Lee et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Lee et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.nutritionj.com/content/12/1/142"/><abstract><sec><title>Background</title><p>High oxidative stress and chronic inflammation can contribute to the pathogenesis of coronary artery disease (CAD). Coenzyme Q10 is an endogenous lipid-soluble antioxidant. Statins therapy can reduce the biosynthesis of coenzyme Q10. The purpose of this study was to investigate the effects of a coenzyme Q10 supplement (300&#x000a0;mg/d; 150&#x000a0;mg/b.i.d) on antioxidation and anti-inflammation in patients who have CAD during statins therapy.</p></sec><sec><title>Methods</title><p>Patients who were identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery and who were treated with statins for at least one month were enrolled in this study. The subjects (n&#x02009;=&#x02009;51) were randomly assigned to the placebo (n&#x02009;=&#x02009;24) and coenzyme Q10 groups (Q10-300 group, n&#x02009;=&#x02009;27). The intervention was administered for 12&#x000a0;weeks. The concentrations of coenzyme Q10, vitamin E, antioxidant enzymes activities (superoxide dismutase, catalase, and glutathione peroxidase), and inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and interleukin-6 (IL-6)] were measured in the 42 subjects (placebo, n&#x02009;=&#x02009;19; Q10-300, n&#x02009;=&#x02009;23) who completed the study.</p></sec><sec><title>Results</title><p>The levels of the plasma coenzyme Q10 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and antioxidant enzymes activities (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) were significantly higher after coenzyme Q10 supplementation. The levels of inflammatory markers (TNF-&#x003b1;, <italic>P</italic>&#x02009;=&#x02009;0.039) were significantly lower after coenzyme Q10 supplementation. The subjects in the Q10-300 group had significantly higher vitamin E (<italic>P</italic>&#x02009;=&#x02009;0.043) and the antioxidant enzymes activities (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) than the placebo group at week 12. The level of plasma coenzyme Q10 was significantly positively correlated with vitamin E (<italic>P</italic>&#x02009;=&#x02009;0.008) and antioxidant enzymes activities (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) and was negatively correlated with TNF-&#x003b1; (<italic>P</italic>&#x02009;=&#x02009;0.034) and IL-6 (<italic>P</italic>&#x02009;=&#x02009;0.027) after coenzyme Q10 supplementation.</p></sec><sec><title>Conclusion</title><p>Coenzyme Q10 supplementation at 300&#x000a0;mg/d significantly enhances antioxidant enzymes activities and lowers inflammation in patients who have CAD during statins therapy.</p></sec><sec><title>Trial registration</title><p>Clinical Trials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01424761">NCT01424761</ext-link>.</p></sec></abstract><kwd-group><kwd>Coenzyme Q10</kwd><kwd>Statins</kwd><kwd>Antioxidation</kwd><kwd>Inflammation</kwd><kwd>Coronary artery disease</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Cardiovascular disease is the leading cause of death worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. Hyperlipidemia is a major risk factor for coronary artery disease (CAD). A higher level of low density lipoprotein-cholesterol (LDL-C) can increase the incidence of CAD [<xref ref-type="bibr" rid="B2">2</xref>]. The 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-Co A reductase) inhibitors (statins) have been the most popular drugs for reducing the level of LDL-C, and they are an established strategy for decreasing the frequency of CAD events [<xref ref-type="bibr" rid="B3">3</xref>]. Coenzyme Q10 (also called ubiquinone) is a lipid-soluble benzoquinone that has 10 isoprenyl units in its side chain and is a key component of the mitochondrial respiratory chain for adenosine triphosphate synthesis [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Statins can decrease the synthesis of cholesterol and other molecules downstream of mevalonate. Mevalonate is a precursor of coenzyme Q10. Statins not only lower the blood cholesterol but also lower the level of coenzyme Q10 [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Higher levels of oxidative stress and inflammation play a role in the development of CAD [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Coenzyme Q10 is an intracellular antioxidant that protects the membrane phospholipids, mitochondrial membrane protein, and LDL-C from free radical-induced oxidative damage [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Recently, we have demonstrated that coenzyme Q10 had a cardio-protective impact on CAD. A higher level of plasma coenzyme Q10 (&#x02265; 0.52&#x000a0;&#x003bc;mol/L) was significantly associated with a reduced the risk of CAD [<xref ref-type="bibr" rid="B14">14</xref>]. We proposed that a higher dose of coenzyme Q10 (&#x0003e; 150&#x000a0;mg/d) might show better antioxidation in patients who have CAD [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>The circulating levels of C-reactive protein (CRP), tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and interleukin-6 (IL-6) are positively correlated with the risk of primary and recurrent myocardial infarction and death [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Adiponectin is an anti-inflammatory marker that is potentially antiatherogenic and is secreted in abundance by adipocytes [<xref ref-type="bibr" rid="B19">19</xref>]. Its level might be related to the development of CAD [<xref ref-type="bibr" rid="B20">20</xref>]. In a recent study [<xref ref-type="bibr" rid="B21">21</xref>], we reported that coenzyme Q10 administered at 150&#x000a0;mg/d decreased the inflammatory marker -IL-6 but had no effect on CRP in patients with CAD. Thus, we hypothesize that a higher dose of coenzyme Q10 (&#x0003e; 150&#x000a0;mg/d) would provide better anti-inflammation in CAD patients. The purpose of this study was to investigate the effect of coenzyme Q10 supplementation (300&#x000a0;mg/day, 150&#x000a0;mg/b.i.d) on antioxidant enzymes activities and anti-inflammation in patients with CAD during statins therapy.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Participants</title><p>This study was designed as a single blinded, randomized, parallel, placebo-controlled study. CAD patients were recruited from the cardiology clinic of Taichung Veterans General Hospital, which is a teaching hospital in central Taiwan. CAD was identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery or receiving percutaneous transluminal coronary angioplasty (PTCA). The subjects in this study were treated with statins therapy for at least 1&#x000a0;month. The subjects with diabetes, liver, or renal diseases, or who currently use vitamin supplements were excluded. Informed consent was obtained from each subject. This study was approved by the Institutional Review Board of Taichung Veterans General Hospital, Taiwan.</p><p>With a sample size calculation, we expected that the change in the levels of antioxidant enzymes activities would be 5.0&#x02009;&#x000b1;&#x02009;7.0 U/mg of protein after coenzyme Q10 supplementation; therefore, the desired power was set at 0.8 to detect a true fact and at an &#x003b1; value equal to 0.05 with a minimal sample of 18 in each intervention group. We enrolled 51 CAD patients in this study and used random numbers table to random assign the subjects to the placebo (n&#x02009;=&#x02009;24) or to the coenzyme Q10 [300&#x000a0;mg/day (Q10-300 group), n&#x02009;=&#x02009;27] groups. The female subjects in this study were postmenopausal women who were not receiving hormone therapy. The coenzyme Q10 and placebo (starch) capsules were commercially available preparations (New Health Taiwan Co., Ltd.). The intervention was administered for 12&#x000a0;weeks. The subjects were instructed to take two capsules daily (coenzyme Q10 supplements 300&#x000a0;mg/d, 150&#x000a0;mg/b.i.d). To monitor compliance, the researchers reminded subjects to check the capsules bag every 4&#x000a0;weeks to confirm that the bag was empty. The researcher also asked some questions to the subjects, such as &#x02460;When did you take the supplements? (We advised subjects to take the supplements after a meal); &#x02461;How many times did you take the supplements every day? (We advised subjects to take the supplements two times per day); &#x02462;How many capsules did you take of the supplements each time? (We advised the subjects to take one capsule of supplement each time); and &#x02463;How did you feel after taking the supplements? (for monitoring adverse effects), and then we checked the capsule bags. We placed 56 capsules in each bag, and the bag should be emptied after 4&#x000a0;weeks of taking the supplements. If the subjects took the empty bag back and answered the questions correctly, the researcher then gave them another bag of capsules. In addition, we also measured the concentration of coenzyme Q10 every 4&#x000a0;weeks supplementation for monitor the compliance of the subjects. The age, blood pressures, and smoking, drinking, and exercise habits of all of the subjects were recorded. The body weight and height were measured; the body mass index (BMI) was then calculated.</p></sec><sec><title>Blood collection and biochemical measurements</title><p>Fasting venous blood samples (15&#x000a0;mL) were obtained to estimate the hematological and vitamin status. Blood specimens were collected in Vacutainer tubes (Becton Dickinson, Rutherford, NJ, USA) that contained EDTA as an anticoagulant or that contained no anticoagulant as required. Serum and plasma were prepared after centrifugation (3,000&#x000a0;rpm, 4&#x000b0;C, 15&#x000a0;minutes) and were then stored at -80&#x000b0;C until analysis. Hematological entities [serum creatinine, total cholesterol (TC), triglyceride, LDL-C, and high density lipoprotein-cholesterol (HDL-C)] were measured by an automated biochemical analyzer (Hitachi-7180E, Tokyo, Japan). The level of CRP was quantified by particle-enhanced immunonephelometry with an Image analyzer (Dade Behring, IL, USA). Plasma TNF-&#x003b1; (R&#x00026;D Systems Inc., Minneapolis, USA), IL-6 (eBioscience, CA, USA), and adiponectin (BioVendor, Brno, Czech Republic) levels were measured by enzyme-linked immunosorbent assay (ELISA) using commercially available kits and according to the instructions made available from the suppliers.</p><p>Plasma coenzyme Q10 and vitamin E were measured by high-performance liquid chromatography (HPLC) and were detected by a UV detector at 275&#x000a0;nm and 292&#x000a0;nm, respectively [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. The red blood cell (RBC) samples were washed with normal saline after removing the plasma. Then, the RBC were diluted with 25x sodium phosphate buffer for superoxide dismutase (SOD) and glutathione peroxidase (GPx) measurements, and with 250x sodium phosphate buffer for catalase (CAT) measurement. The antioxidant enzymes activities (CAT, SOD, and GPx) were determined in the fresh samples and the methods for measuring these activities have been described previously [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. The protein content of the plasma and RBC was determined based on the biuret reaction of the BCA kit (Thermo, Rockford, IL, USA). The values of the antioxidant enzymes activities were expressed as unit/mg of protein. All of the analyses were performed in duplicate.</p></sec><sec><title>Statistical analyses</title><p>The data were analyzed using SigmaPlot software (version 12.0, Systat, San Jose, CA, USA). The normality of the distribution of the variables was evaluated using the Shapiro-Wilk test, and the normally distributed variables were age, waist circumference, the ratio of waist to hip, BMI, TC, LDL-C, HDL-C, the frequency of smoking and exercise, the ratio of vitamin E to TC, SOD, and IL-6. The multiple linear regression analyses were performed to examine the time and the interventional effects on the variables (coenzyme Q10, vitamin E, antioxidant enzymes, and inflammation markers as a dependent variable). We set the dummy variables for the time (0&#x02009;=&#x02009;baseline, 1&#x02009;=&#x02009;week 12) and the intervention (0&#x02009;=&#x02009;placebo, 1&#x02009;=&#x02009;coenzyme Q10 supplementation). If the variables had significantly effects by the time or the intervention, then the intergroup differences (intervention effect) between the placebo and the Q10-300 groups were evaluated by the Student&#x02019;s t-test or the Mann-Whitney rank sum test; within a group (time effect), the paired t-test or the Wilcoxon signed rank tests were used. When comparing the changed levels of coenzyme Q10, vitamin E, antioxidant enzymes activities and inflammatory markers between the placebo and the Q10-300 groups, the Student&#x02019;s t-test or the Mann-Whitney rank sum test was used. For categorical response variables, the differences between two groups were assessed by the Chi-square test (parametric method) or the Fisher&#x02019;s exact test (non-parametric method). To examine the relationships of coenzyme Q10 concentration with the level of vitamin E, antioxidant enzymes activities, and inflammatory markers after the supplementation, the Pearson product moment correlations were used in the parametric data and the Spearman rank order correlations were used in the non-parametric data. The results were considered to be statistically significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. The values presented in the text are means&#x02009;&#x000b1;&#x02009;standard deviation (SD).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Study participant characteristics</title><p>The sampling and trial profiles are summarized in Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>, along with the number of subjects who completed the study in each group. Table&#x000a0;<xref ref-type="table" rid="T1">1</xref> shows the demographic data and the health characteristics of the subjects. There were no significant differences between the two groups with respect to age, BMI, blood pressure, anthropometric measurements, hematological entities (serum creatinine and lipid profiles), and the frequency of smoking, drinking, or exercise at baseline.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Flow diagram.</bold> Q10-300, coenzyme Q10 300&#x000a0;mg/d.</p></caption><graphic xlink:href="1475-2891-12-142-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of subjects</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="center"><bold>Placebo (n&#x02009;=&#x02009;19)</bold></th><th align="center"><bold>Q10-300 (n&#x02009;=&#x02009;23)</bold></th><th align="center"><bold>
<italic>P </italic>
</bold><bold>values</bold><sup>
<bold>1</bold>
</sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Male / female (n)<hr/></td><td align="center" valign="bottom">12 / 7<hr/></td><td align="center" valign="bottom">19 / 4<hr/></td><td align="center" valign="bottom">0.180<sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">Age (y)<hr/></td><td align="center" valign="bottom">66.5&#x02009;&#x000b1;&#x02009;11.1 (68.0)<hr/></td><td align="center" valign="bottom">71.7&#x02009;&#x000b1;&#x02009;11.5 (72.0)<hr/></td><td align="center" valign="bottom">0.148<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">SBP (mmHg)<hr/></td><td align="center" valign="bottom">133.6&#x02009;&#x000b1;&#x02009;6.9 (130.0)<hr/></td><td align="center" valign="bottom">131.8&#x02009;&#x000b1;&#x02009;12.0 (130.0)<hr/></td><td align="center" valign="bottom">0.175<sup>c</sup><hr/></td></tr><tr><td align="left" valign="bottom">DBP (mmHg)<hr/></td><td align="center" valign="bottom">75.5&#x02009;&#x000b1;&#x02009;5.2 (74.0)<hr/></td><td align="center" valign="bottom">73.8&#x02009;&#x000b1;&#x02009;7.1 (70.0)<hr/></td><td align="center" valign="bottom">0.234<sup>c</sup><hr/></td></tr><tr><td align="left" valign="bottom">Waist circumference (cm)<hr/></td><td align="center" valign="bottom">95.2&#x02009;&#x000b1;&#x02009;10.0 (96.0)<hr/></td><td align="center" valign="bottom">92.1&#x02009;&#x000b1;&#x02009;11.3 (90.0)<hr/></td><td align="center" valign="bottom">0.362<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">Waist hip ratio<hr/></td><td align="center" valign="bottom">1.0&#x02009;&#x000b1;&#x02009;0.1 (0.9)<hr/></td><td align="center" valign="bottom">0.9&#x02009;&#x000b1;&#x02009;0.1 (0.9)<hr/></td><td align="center" valign="bottom">0.743<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">BMI (kg/m<sup>2</sup>)<hr/></td><td align="center" valign="bottom">26.7&#x02009;&#x000b1;&#x02009;3.2 (26.5)<hr/></td><td align="center" valign="bottom">25.9&#x02009;&#x000b1;&#x02009;3.5 (25.3)<hr/></td><td align="center" valign="bottom">0.438<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">Current smoker<sup>2</sup>, n (%)<hr/></td><td align="center" valign="bottom">4 (21.1%)<hr/></td><td align="center" valign="bottom">1 (4.3%)<hr/></td><td align="center" valign="bottom">0.158<sup>d</sup><hr/></td></tr><tr><td align="left" valign="bottom">Drink alcohol<sup>3</sup>, n (%)<hr/></td><td align="center" valign="bottom">2 (10.5%)<hr/></td><td align="center" valign="bottom">3 (13.0%)<hr/></td><td align="center" valign="bottom">1.000<sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">Exercise<sup>4</sup>, n (%)<hr/></td><td align="center" valign="bottom">13 (68.4%)<hr/></td><td align="center" valign="bottom">15 (65.2%)<hr/></td><td align="center" valign="bottom">0.913<sup>d</sup><hr/></td></tr><tr><td align="left" valign="bottom">Creatinine (&#x003bc;mol/L)<hr/></td><td align="center" valign="bottom">123.8&#x02009;&#x000b1;&#x02009;70.7 (106.1)<hr/></td><td align="center" valign="bottom">114.9&#x02009;&#x000b1;&#x02009;44.2 (97.2)<hr/></td><td align="center" valign="bottom">0.780<sup>c</sup><hr/></td></tr><tr><td align="left" valign="bottom">TC (mmol/L)<hr/></td><td align="center" valign="bottom">4.5&#x02009;&#x000b1;&#x02009;1.3 (4.4)<hr/></td><td align="center" valign="bottom">5.0&#x02009;&#x000b1;&#x02009;1.0 (4.9)<hr/></td><td align="center" valign="bottom">0.175<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">TG (mmol/L)<hr/></td><td align="center" valign="bottom">1.7&#x02009;&#x000b1;&#x02009;1.3 (1.3)<hr/></td><td align="center" valign="bottom">1.6&#x02009;&#x000b1;&#x02009;0.9 (1.4)<hr/></td><td align="center" valign="bottom">0.791<sup>c</sup><hr/></td></tr><tr><td align="left" valign="bottom">LDL-C (mmol/L)<hr/></td><td align="center" valign="bottom">2.7&#x02009;&#x000b1;&#x02009;0.8 (2.5)<hr/></td><td align="center" valign="bottom">3.0&#x02009;&#x000b1;&#x02009;0.8 (3.1)<hr/></td><td align="center" valign="bottom">0.165<sup>b</sup><hr/></td></tr><tr><td align="left">HDL-C (mmol/L)</td><td align="center">1.4&#x02009;&#x000b1;&#x02009;0.4 (1.4)</td><td align="center">1.4&#x02009;&#x000b1;&#x02009;0.3 (1.4)</td><td align="center">0.984<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Data are mean &#x000b1; SD (median).</p><p><sup>1</sup>values are significantly different between the placebo and Q10-300 groups.</p><p><sup>2</sup>current smoker: individual currently smoking one or more cigarettes per day.</p><p><sup>3</sup>drink alcohol: individual drinking one or more drink per day regularly.</p><p><sup>4</sup>exercise: individual exercise at least 3 times every week.</p><p><sup>a</sup>data were analyzed by the Fisher&#x02019;s exact test.</p><p><sup>b</sup>data were analyzed by the Student&#x02019;s t-test.</p><p><sup>c</sup>data were analyzed by the Mann-Whitney rank sum test.</p><p><sup>d</sup>data were analyzed by the Chi-square test.</p><p><italic>BMI</italic>, body mass index; <italic>DBP</italic>, diastolic blood pressure; <italic>HDL-C</italic>, high-density lipoprotein-cholesterol; <italic>LDL-C</italic>, low density lipoprotein-cholesterol; <italic>SBP</italic>, systolic blood pressure; <italic>TC</italic>, total cholesterol; <italic>TG</italic>, triglyceride.</p></table-wrap-foot></table-wrap></sec><sec><title>Plasma coenzyme Q10 and vitamin E concentrations</title><p>The effects of coenzyme Q10 supplementation on the levels of coenzyme Q10 and vitamin E are shown in Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>. The plasma coenzyme Q10 concentration (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and the ratio of coenzyme Q10 to TC (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) were significantly increased after coenzyme Q10 supplementation. The subjects in the Q10-300 group had significantly higher levels of coenzyme Q10 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), ratio of coenzyme Q10 to TC (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and vitamin E (<italic>P</italic>&#x02009;=&#x02009;0.043), and ratio of vitamin E to TC (<italic>P</italic>&#x02009;=&#x02009;0.025) than those in the placebo group at week 12.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Coenzyme Q10 and vitamin E concentrations.</bold> Data are means &#x000b1; SD. &#x025a1; week 0, &#x025a0; week 12. *Values were significantly different after intervention within the group (<sup>***</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). &#x02020;Values were significantly different between the placebo and Q10-300 groups (<sup>&#x02020;</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>&#x02020;&#x02020;&#x02020;</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). TC, total cholesterol.</p></caption><graphic xlink:href="1475-2891-12-142-2"/></fig></sec><sec><title>Antioxidant enzymes activities</title><p>The effects of coenzyme Q10 supplementation on the antioxidant enzymes activities are shown in Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>. The activities of SOD (<italic>P</italic>&#x02009;=&#x02009;0.001), CAT (<italic>P</italic>&#x02009;=&#x02009;0.009), and GPx (<italic>P</italic>&#x02009;=&#x02009;0.021) were significantly increased after coenzyme Q10 supplementation. The subjects in the Q10-300 group had significantly higher activities of SOD (<italic>P</italic>&#x02009;=&#x02009;0.005), CAT (<italic>P</italic>&#x02009;=&#x02009;0.025), and GPx (<italic>P</italic>&#x02009;=&#x02009;0.040) than those in the placebo group at week 12.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Antioxidant enzymes activities.</bold> Data are means &#x000b1; SD. &#x025a1; week 0, &#x025a0; week 12. *Values were significantly different after intervention within the group (<sup>*</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>**</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01). &#x02020;Values were significantly different between the placebo and Q10-300 groups (<sup>&#x02020;</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>&#x02020;&#x02020;</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01). CAT, catalase; GPx, glutathione peroxidase; SOD, superoxide dismutase.</p></caption><graphic xlink:href="1475-2891-12-142-3"/></fig></sec><sec><title>Inflammatory markers</title><p>The effects of coenzyme Q10 supplementation on the levels of inflammatory markers are shown in Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>. The subjects in the Q10-300 group had a significantly lower level of TNF-&#x003b1; than those in the placebo group at week 12 (<italic>P</italic>&#x02009;=&#x02009;0.039). There were no effects on the level of CRP, IL-6, and adiponectin after 12&#x000a0;weeks of supplementation.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>The level of inflammatory markers.</bold> Data are means &#x000b1; SD. &#x025a1; week 0, &#x025a0; week 12. &#x02020;Values were significantly different between the placebo and Q10-300 groups (<sup>&#x02020;</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). CRP, C-reactive protein; IL-6, interleukin-6; TNF-&#x003b1;, tumor necrosis factor-&#x003b1;.</p></caption><graphic xlink:href="1475-2891-12-142-4"/></fig></sec><sec><title>Changed levels of coenzyme Q10, vitamin E, antioxidant enzymes activities, and inflammatory markers after supplementation</title><p>The changed levels of coenzyme Q10, vitamin E, antioxidant enzymes activities, and inflammatory markers after the supplementation are shown in Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>. The Changed levels of coenzyme Q10 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), the ratios of coenzyme Q10 to TC (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), vitamin E (<italic>P</italic>&#x02009;=&#x02009;0.046), the ratios of vitamin E to TC (<italic>P</italic>&#x02009;=&#x02009;0.032), antioxidant enzymes activities (SOD, <italic>P</italic>&#x02009;=&#x02009;0.034; CAT, <italic>P</italic>&#x02009;=&#x02009;0.033; GPx, <italic>P</italic>&#x02009;=&#x02009;0.042), and inflammatory markers (TNF-&#x003b1;, <italic>P</italic>&#x02009;=&#x02009;0.036; IL-6, <italic>P</italic>&#x02009;=&#x02009;0.040) were significantly different between the placebo and the Q10-300 groups.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Changed levels of coenzyme Q10, vitamin E, antioxidant enzymes activities, and inflammatory markers after supplementation</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="center"><bold>Placebo (n&#x02009;=&#x02009;19)</bold></th><th align="center"><bold>Q10-300 (n&#x02009;=&#x02009;23)</bold></th><th align="center"><bold>
<italic>P </italic>
</bold><bold>values</bold><sup>
<bold>1</bold>
</sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Coenzyme Q10 (&#x003bc;mol/L)<hr/></td><td align="center" valign="bottom">&#x02212;0.01&#x02009;&#x000b1;&#x02009;0.09 (-0.03)<hr/></td><td align="center" valign="bottom">1.10&#x02009;&#x000b1;&#x02009;0.54 (1.26)<hr/></td><td align="center" valign="bottom">&#x0003c; 0.001<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">Coenzyme Q10/TC (&#x003bc;mol/mmol)<hr/></td><td align="center" valign="bottom">&#x02212;0.01&#x02009;&#x000b1;&#x02009;0.07 (-0.00)<hr/></td><td align="center" valign="bottom">0.25&#x02009;&#x000b1;&#x02009;0.11 (0.25)<hr/></td><td align="center" valign="bottom">&#x0003c; 0.001<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">Vitamin E (&#x003bc;mol/L)<hr/></td><td align="center" valign="bottom">&#x02212;3.35&#x02009;&#x000b1;&#x02009;4.51 (-3.08)<hr/></td><td align="center" valign="bottom">&#x02212;0.29&#x02009;&#x000b1;&#x02009;4.03 (-0.83)<hr/></td><td align="center" valign="bottom">0.046<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">Vitamin E/TC (&#x003bc;mol/mmol)<hr/></td><td align="center" valign="bottom">&#x02212;0.88&#x02009;&#x000b1;&#x02009;1.45 (-0.55)<hr/></td><td align="center" valign="bottom">0.07&#x02009;&#x000b1;&#x02009;1.08 (0.11)<hr/></td><td align="center" valign="bottom">0.032<sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">SOD (U/mg protein)<hr/></td><td align="center" valign="bottom">1.63&#x02009;&#x000b1;&#x02009;21.54 (3.63)<hr/></td><td align="center" valign="bottom">15.90&#x02009;&#x000b1;&#x02009;20.48 (12.91)<hr/></td><td align="center" valign="bottom">0.034<sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">CAT (U/mg protein)<hr/></td><td align="center" valign="bottom">&#x02212;1.42&#x02009;&#x000b1;&#x02009;8.26 (-1.18)<hr/></td><td align="center" valign="bottom">6.17&#x02009;&#x000b1;&#x02009;11.28 (3.18)<hr/></td><td align="center" valign="bottom">0.033<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">GPx (U/mg protein)<hr/></td><td align="center" valign="bottom">0.91&#x02009;&#x000b1;&#x02009;3.70 (-0.24)<hr/></td><td align="center" valign="bottom">4.62&#x02009;&#x000b1;&#x02009;6.52 (2.15)<hr/></td><td align="center" valign="bottom">0.042<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">CRP (mg/L)<hr/></td><td align="center" valign="bottom">0.39&#x02009;&#x000b1;&#x02009;1.24 (0.00)<hr/></td><td align="center" valign="bottom">&#x02212;0.20&#x02009;&#x000b1;&#x02009;0.73 (0.00)<hr/></td><td align="center" valign="bottom">0.343<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">TNF-&#x003b1; (pg/mL)<hr/></td><td align="center" valign="bottom">0.17&#x02009;&#x000b1;&#x02009;0.77 (0.08)<hr/></td><td align="center" valign="bottom">&#x02212;0.30&#x02009;&#x000b1;&#x02009;0.35 (-0.26)<hr/></td><td align="center" valign="bottom">0.036<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">IL-6 (pg/mL)<hr/></td><td align="center" valign="bottom">0.08&#x02009;&#x000b1;&#x02009;0.64 (-0.11)<hr/></td><td align="center" valign="bottom">&#x02212;0.52&#x02009;&#x000b1;&#x02009;0.79 (-0.14)<hr/></td><td align="center" valign="bottom">0.040<sup>a</sup><hr/></td></tr><tr><td align="left">Adiponectin (&#x003bc;g/mL)</td><td align="center">0.36&#x02009;&#x000b1;&#x02009;2.89 (0.30)</td><td align="center">0.19&#x02009;&#x000b1;&#x02009;1.88 (-0.20)</td><td align="center">0.71<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Data are mean &#x000b1; SD (median).</p><p><sup>1</sup>values are significantly different between the placebo and the Q10-300 groups.</p><p><sup>a</sup>data were analyzed by the Student&#x02019;s t-test.</p><p><sup>b</sup>data were analyzed by the Mann-Whitney rank sum test.</p><p><italic>CAT</italic>, catalase; <italic>CRP</italic>, C-reactive protein; <italic>GPx</italic>, glutathione peroxidase; <italic>IL-6</italic>, interleukin-6; <italic>SOD</italic>, superoxide dismutase; <italic>TC</italic>, total cholesterol; <italic>TNF-&#x003b1;</italic>, tumor necrosis factor-&#x003b1;.</p></table-wrap-foot></table-wrap></sec><sec><title>Correlations between coenzyme Q10, vitamin E, antioxidant enzymes activities, and inflammatory markers</title><p>The correlations between coenzyme Q10, vitamin E, antioxidant enzymes activities, and inflammatory markers after coenzyme Q10 supplementation are shown in Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>. The plasma coenzyme Q10 concentration was significantly correlated with the vitamin E (<italic>r</italic>&#x02009;=&#x02009;0.41, <italic>P</italic>&#x02009;=&#x02009;0.008), antioxidant enzymes activities (SOD, <italic>r</italic>&#x02009;=&#x02009;0.38, <italic>P</italic>&#x02009;=&#x02009;0.011; CAT, <italic>r</italic>&#x02009;=&#x02009;0.30, <italic>P</italic>&#x02009;=&#x02009;0.0038; GPx, <italic>r</italic>&#x02009;=&#x02009;0.32, <italic>P</italic>&#x02009;=&#x02009;0.043), and the inflammatory markers (TNF-&#x003b1;, <italic>r</italic>&#x02009;=&#x02009;-0.33, <italic>P</italic>&#x02009;=&#x02009;0.034; IL-6, <italic>r</italic>&#x02009;=&#x02009;-0.38, <italic>P</italic>&#x02009;=&#x02009;0.027) at week 12.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Correlations between coenzyme Q10, vitamin E, antioxidant enzymes activities, and inflammatory markers after coenzyme Q10 supplementation</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="center"><bold>Coenzyme Q10 (&#x003bc;mol/L) </bold><bold>
<italic>r</italic>
</bold><sup>
<bold>1 </bold>
</sup><bold>(</bold><bold>
<italic>P </italic>
</bold><bold>values)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Vitamin E (&#x003bc;mol/L)<hr/></td><td align="center" valign="bottom">0.41 (0.008)<sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">SOD (unit/mg protein)<hr/></td><td align="center" valign="bottom">0.38 (0.011)<sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">CAT (unit/mg protein)<hr/></td><td align="center" valign="bottom">0.30 (0.038)<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">GPx (unit/mg protein)<hr/></td><td align="center" valign="bottom">0.32 (0.043)<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">CRP (mg/L)<hr/></td><td align="center" valign="bottom">&#x02212;0.08 (0.621)<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">TNF-&#x003b1; (pg/mL)<hr/></td><td align="center" valign="bottom">&#x02212;0.33 (0.034)<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">IL-6 (pg/mL)<hr/></td><td align="center" valign="bottom">&#x02212;0.38 (0.027)<sup>a</sup><hr/></td></tr><tr><td align="left">Adiponectin (&#x003bc;g/mL)</td><td align="center">&#x02212;0.21 (0.190)<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>correlation coefficient.</p><p><sup>a</sup>data were analyzed by the Pearson product moment correlation.</p><p><sup>b</sup>data were analyzed by the Spearman rank order correlation.</p><p>CAT, catalase; CRP, C-reactive protein; GPx, glutathione peroxidase; IL-6, interleukin-6; SOD, superoxide dismutase; TNF-&#x003b1;, tumor necrosis factor-&#x003b1;.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this clinical trial, we have demonstrated that coenzyme Q10 at the dose of 300&#x000a0;mg/d for 12&#x000a0;weeks increases the antioxidant enzymes activities (SOD, CAT, and GPx) and decreases inflammation in patients with CAD during statins therapy. Tiano et al. [<xref ref-type="bibr" rid="B27">27</xref>] administered coenzyme Q10 (300&#x000a0;mg/d) to patients with ischemic heart disease for 1&#x000a0;month, and they observed that those patients&#x02019; extracellular superoxide dismutase activity and endothelium-dependent vasodilatation were improved after supplementation. Antioxidant enzymes such as SOD, CAT, and GPx are the first line of defense against reactive oxygen species [<xref ref-type="bibr" rid="B28">28</xref>], and a decrease in their activities contributes to the elevated oxidative stress in CAD patients [<xref ref-type="bibr" rid="B14">14</xref>]. Our previous results showed that coenzyme Q10 at a dose of 150&#x000a0;mg/d increased the activity of SOD by 22.2% and of CAT by 4.5%, but had no effect on that of GPx [<xref ref-type="bibr" rid="B15">15</xref>]. In the present study, coenzyme Q10 supplementation at 300&#x000a0;mg/d increased the activity of SOD by 48.5%, CAT by 9.1%, and GPx by 4.3%, and the antioxidant enzymes activities were all positively correlated with the level of coenzyme Q10 after 12&#x000a0;weeks of supplementation (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). It appears that the 300&#x000a0;mg dose of coenzyme Q10 has better antioxidation than 150&#x000a0;mg/d.</p><p>Both groups of statins-treated CAD patients in this study had a low level of coenzyme Q10 at baseline (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>), and the level of coenzyme Q10 was significantly increased by approximately 5-fold after 4&#x000a0;weeks of coenzyme Q10 supplementation (data not shown; the median level of coenzyme Q10 was 0.4 to 2.0&#x000a0;&#x003bc;mol/L), which rapidly adjusted their low coenzyme Q10 level to normal values (0.5 &#x02013; 1.7&#x000a0;&#x003bc;mol/L) [<xref ref-type="bibr" rid="B29">29</xref>]. In addition, coenzyme Q10 had a synergic effect with vitamin E [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B33">33</xref>]. In this study, we observed that the level of vitamin E was significantly higher in the Q10-300 group (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>) and was positively correlated with the level of coenzyme Q10 after 12&#x000a0;weeks of supplementation (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). Coenzyme Q10 not only protects vitamin E against superoxide-driven oxidation but also regenerates vitamin E during antioxidation processes [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>].</p><p>CAD is considered to be a chronic inflammation status [<xref ref-type="bibr" rid="B10">10</xref>]. In the present study, the level of TNF-&#x003b1; (Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>) and the changed levels of TNF-&#x003b1; and IL-6 were significantly decreased after coenzyme Q10 supplementation (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). The level of coenzyme Q10 was significantly negatively correlated with inflammatory markers (TNF-&#x003b1; and IL-6) (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). Schmelzer et al. [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>] demonstrated that coenzyme Q10 could exert anti-inflammation effects via the reduction of nuclear factor-&#x003ba;B (NF-&#x003ba;B) dependent gene expression. NF-&#x003ba;B can be activated by the reactive oxygen species and can then up-regulate pro-inflammatory cytokines expression. However, this NF-&#x003ba;B -activating cascade could be inhibited by antioxidants, such as coenzyme Q10 [<xref ref-type="bibr" rid="B36">36</xref>]. Our previous results [<xref ref-type="bibr" rid="B21">21</xref>] showed that coenzyme Q10 at a dose of 150&#x000a0;mg/d decreased the level of IL-6 by 0.40&#x000a0;pg/mL. In the present study, coenzyme Q10 supplementation at 300&#x000a0;mg/d decreased the levels of TNF-&#x003b1; by 0.30&#x000a0;pg/mL and IL-6 by 0.52&#x000a0;pg/mL. However, coenzyme Q10 supplementation had no effect on the level of CRP. As we previously reported, proinflammatory cytokines (TNF-&#x003b1; and IL-6) reflect the status of inflammatory reactions with more sensitivity (easily changed) than CRP, which is a product of hepatic stimulation [<xref ref-type="bibr" rid="B21">21</xref>]. A higher level of adiponectin is associated with a lower risk of CAD [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B37">37</xref>], but coenzyme Q10 supplementation had no effect on the level of adiponectin in the present study. Nakamura et al. [<xref ref-type="bibr" rid="B20">20</xref>] reported that the concentration of plasma adiponectin was not significantly different between stable angina pectoris and control subjects. The subjects who had CAD in this study had not experienced acute myocardial infarction within the previous 6&#x000a0;months and thus were stable angina pectoris patients, which might be the reason why we did not find an effect of coenzyme Q10 on adiponectin.</p><p>Regarding the safety of statins therapy and its combination with placebo or coenzyme Q10 in the present study, there were no clinically significant changes in the subjects&#x02019; vital signs, serum chemical values, or hematological values, and there were no serious adverse events, no complaints of myalgia or muscle weakness, and no withdrawals due to adverse events. Thus, coenzyme Q10 at a dose of 300&#x000a0;mg/d is safe for co-administration with statins therapy.</p><p>Two limitations of the present study should be mentioned. First, the number of participants was small, although we did recruit more subjects than expected. Second, a few of the subjects had higher inflammation in the present study. Only 10% of the subjects had a high inflammation according to the level of CRP (&#x02265; 3.0&#x000a0;mg/L), and this finding might have contributed to observing the null effect on CRP after the supplementation. Large studies are needed to establish the beneficial effect of coenzyme Q10 supplementation on inflammation, especially in subjects who have high inflammation status.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In conclusion, we have demonstrated that coenzyme Q10 supplementation at a dose of 300&#x000a0;mg/d significantly increased antioxidant enzymes activities and reduced the levels of inflammatory markers (TNF-&#x003b1; and IL-6) in CAD patients during statins therapy. CAD patients might benefit from using coenzyme Q10 supplements to increase their antioxidation and anti-inflammation capacity during statins therapy.</p></sec><sec><title>Competing interests</title><p>The authors have no conflict of interest.</p></sec><sec><title>Authors&#x02019; contributions</title><p>BJL carried out the study, performed the data analyses, and drafted the manuscript. YFT and CHY carried out the study and sample analyses. PTL conceived of the study, participated in its design, and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgments</title><p>This study was supported by a grant from the National Science Council (NSC 100-2320-B-040-003), Taiwan. We would like to express our sincere appreciation to the subjects for their participation and to Dr. Hsia, who kindly provided the coenzyme Q10 supplements for this trial. We thank the nurses at Taichung Veterans General Hospital and the technical advisor of Taipei Institute of Pathology for providing expert assistance in blood sample collection and data analysis.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Braunwald</surname><given-names>E</given-names></name><article-title>Shattuck lecture&#x02013;cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities</article-title><source>N Engl J Med</source><year>1997</year><volume>337</volume><fpage>1360</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1056/NEJM199711063371906</pub-id><pub-id pub-id-type="pmid">9358131</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><article-title>Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT)</article-title><source>JAMA</source><year>1986</year><volume>256</volume><fpage>2823</fpage><lpage>2828</lpage><pub-id pub-id-type="doi">10.1001/jama.1986.03380200061022</pub-id><pub-id pub-id-type="pmid">3773199</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>LaRosa</surname><given-names>JC</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Waters</surname><given-names>DD</given-names></name><name><surname>Shear</surname><given-names>C</given-names></name><name><surname>Barter</surname><given-names>P</given-names></name><name><surname>Fruchart</surname><given-names>JC</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names></name><name><surname>Greten</surname><given-names>H</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><collab>Treating to New Targets (TNT) Investigators</collab><article-title><bold>Intensive lipid lowering with atorvastatin in patients with stable coronary disease</bold></article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1425</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050461</pub-id><pub-id pub-id-type="pmid">15755765</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Ernster</surname><given-names>L</given-names></name><name><surname>Dallner</surname><given-names>G</given-names></name><article-title>Biochemical, physiological and medical aspects of ubiquinone function</article-title><source>Biochim Giophys Acta</source><year>1995</year><volume>1271</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/0925-4439(95)00028-3</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Bhagavan</surname><given-names>HN</given-names></name><name><surname>Chopra</surname><given-names>RK</given-names></name><article-title>Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics</article-title><source>Free Radic Res</source><year>2006</year><volume>40</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1080/10715760600617843</pub-id><pub-id pub-id-type="pmid">16551570</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Folkers</surname><given-names>K</given-names></name><name><surname>Langsjoen</surname><given-names>P</given-names></name><name><surname>Willis</surname><given-names>R</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Xia</surname><given-names>LJ</given-names></name><name><surname>Ye</surname><given-names>CQ</given-names></name><name><surname>Tamagawa</surname><given-names>H</given-names></name><article-title>Lovastatin decreases coenzyme Q10 levels in human</article-title><source>Proc Natl Acad Sci U S A</source><year>1990</year><volume>87</volume><fpage>8931</fpage><lpage>8934</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.22.8931</pub-id><pub-id pub-id-type="pmid">2247468</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Ghirlanda</surname><given-names>G</given-names></name><name><surname>Oradei</surname><given-names>A</given-names></name><name><surname>Manto</surname><given-names>A</given-names></name><name><surname>Lippa</surname><given-names>S</given-names></name><name><surname>Uccioli</surname><given-names>L</given-names></name><name><surname>Caputo</surname><given-names>S</given-names></name><name><surname>Greco</surname><given-names>AV</given-names></name><name><surname>Littarru</surname><given-names>GR</given-names></name><article-title>Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study</article-title><source>J Clin Pharmacol</source><year>1993</year><volume>33</volume><fpage>26</fpage><lpage>29</lpage></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Mabuchi</surname><given-names>H</given-names></name><name><surname>Higashikata</surname><given-names>T</given-names></name><name><surname>Kawashiri</surname><given-names>M</given-names></name><name><surname>Katsuda</surname><given-names>S</given-names></name><name><surname>Mizuno</surname><given-names>M</given-names></name><name><surname>Nohara</surname><given-names>A</given-names></name><name><surname>Inazu</surname><given-names>A</given-names></name><name><surname>Koizumi</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>A</given-names></name><article-title>Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients</article-title><source>J Atheroscler Thromb</source><year>2005</year><volume>12</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.5551/jat.12.111</pub-id><pub-id pub-id-type="pmid">15942122</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>CS</given-names></name><name><surname>Kou</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>KT</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Voon</surname><given-names>WC</given-names></name><name><surname>Sheu</surname><given-names>SH</given-names></name><name><surname>Lai</surname><given-names>WT</given-names></name><article-title>Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia</article-title><source>Biofactors</source><year>2006</year><volume>28</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1002/biof.5520280304</pub-id><pub-id pub-id-type="pmid">17473378</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Harrison</surname><given-names>D</given-names></name><name><surname>Griendling</surname><given-names>KG</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Hornig</surname><given-names>B</given-names></name><name><surname>Drexlar</surname><given-names>H</given-names></name><article-title>Role of oxidative stress in atherosclerosis</article-title><source>Am J Cardiol</source><year>2003</year><volume>91</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(02)03144-2</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Raychaudhuri</surname><given-names>SP</given-names></name><name><surname>Raychaudhuri</surname><given-names>SK</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name><article-title>Inflammation, atherosclerosis, and psoriasis</article-title><source>Clin Rev Allergy Immunol</source><year>2013</year><volume>44</volume><fpage>194</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1007/s12016-012-8308-0</pub-id><pub-id pub-id-type="pmid">22359071</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Alleva</surname><given-names>R</given-names></name><name><surname>Tomasetti</surname><given-names>M</given-names></name><name><surname>Battino</surname><given-names>M</given-names></name><name><surname>Curatola</surname><given-names>G</given-names></name><name><surname>Littarru</surname><given-names>GP</given-names></name><name><surname>Folkers</surname><given-names>K</given-names></name><article-title>The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>26</volume><fpage>9388</fpage><lpage>9391</lpage><pub-id pub-id-type="pmid">7568138</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name><article-title>Coenzyme Q10 supplementation and heart failure</article-title><source>Nutr Rev</source><year>2007</year><volume>1</volume><fpage>286</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">17605305</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>YC</given-names></name><name><surname>Ko</surname><given-names>YW</given-names></name><name><surname>Hsia</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>PT</given-names></name><article-title>The relationship between coenzyme Q10 and oxidative stress, antioxidant enzymes activities and coronary artery disease</article-title><source>ScientificWorldJournal</source><year>2012</year><volume>2012</volume><fpage>792756</fpage><pub-id pub-id-type="pmid">22645453</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Lin</surname><given-names>PT</given-names></name><article-title>Coenzyme Q10 supplements reduce oxidative stress and increase activities of antioxidant enzymes in patients with coronary artery disease</article-title><source>Nutrition</source><year>2012</year><volume>28</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2011.06.004</pub-id><pub-id pub-id-type="pmid">21996047</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><article-title>A prospective study of fibrinogen and risk of myocardial infarction in the Physicians&#x02019; health study</article-title><source>J Am Coll Cardiol</source><year>1999</year><volume>33</volume><fpage>1347</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(99)00007-8</pub-id><pub-id pub-id-type="pmid">10193737</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Sacks</surname><given-names>F</given-names></name><name><surname>Lepage</surname><given-names>S</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><article-title>Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>2149</fpage><lpage>2153</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.18.2149</pub-id><pub-id pub-id-type="pmid">10801754</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><article-title>Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.15.1767</pub-id><pub-id pub-id-type="pmid">10769275</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Dandona</surname><given-names>P</given-names></name><name><surname>Aljada</surname><given-names>A</given-names></name><name><surname>Chaudhuri</surname><given-names>A</given-names></name><name><surname>Mohanty</surname><given-names>P</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><article-title>Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>1448</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000158483.13093.9D</pub-id><pub-id pub-id-type="pmid">15781756</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>D</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Ehara</surname><given-names>S</given-names></name><name><surname>Hirose</surname><given-names>M</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><name><surname>Kamimori</surname><given-names>K</given-names></name><name><surname>Shimodozono</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Yoshiyama</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>J</given-names></name><article-title>Implications of plasma concentrations of adiponectin in patients with coronary artery disease</article-title><source>Heart</source><year>2004</year><volume>90</volume><fpage>528</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1136/hrt.2003.011114</pub-id><pub-id pub-id-type="pmid">15084551</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Lin</surname><given-names>PT</given-names></name><article-title>Effects of coenzyme Q10 supplementation on inflammatory markers (high sensitivity C-reactive protein, interleukin-6 and homocysteine) in patients with coronary artery</article-title><source>Nutrition</source><year>2012</year><volume>28</volume><fpage>767</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2011.11.008</pub-id><pub-id pub-id-type="pmid">22342390</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Karpi&#x00144;ska</surname><given-names>J</given-names></name><name><surname>Miko&#x00142;u&#x00107;</surname><given-names>B</given-names></name><name><surname>Motkowski</surname><given-names>R</given-names></name><name><surname>Piotrowska-Jastrzebska</surname><given-names>J</given-names></name><article-title>HPLC method for simultaneous determination of retinol, alpha-tocopherol and coenzyme Q10 in human plasma</article-title><source>J Pharm Biomed Anal</source><year>2006</year><volume>42</volume><fpage>232</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2006.03.037</pub-id><pub-id pub-id-type="pmid">16765550</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Littarru</surname><given-names>GP</given-names></name><name><surname>Mosca</surname><given-names>F</given-names></name><name><surname>Fattorini</surname><given-names>D</given-names></name><name><surname>Bompadre</surname><given-names>S</given-names></name><article-title>Method to assay coenzyme Q10 in blood plasma or blood serum</article-title><source>U S Pat</source><year>2007</year><volume>7303921</volume></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Paglia</surname><given-names>D</given-names></name><name><surname>Valentine</surname><given-names>W</given-names></name><article-title>Studies on the qualitative characterization of erythrocyte glutathione peroxidase</article-title><source>J Lab Clin Med</source><year>1967</year><volume>70</volume><fpage>159</fpage><lpage>169</lpage></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Marklund</surname><given-names>S</given-names></name><name><surname>Marklund</surname><given-names>G</given-names></name><article-title>Involvement of superoxide anion radical in autoxidation of pyrogallol and a convenient assay for superoxide dismutase</article-title><source>Eur J Biochem</source><year>1974</year><volume>47</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1974.tb03714.x</pub-id><pub-id pub-id-type="pmid">4215654</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Aebi</surname><given-names>H</given-names></name><article-title>Catalase in vitro. Methods</article-title><source>Enzymol</source><year>1984</year><volume>105</volume><fpage>121</fpage><lpage>126</lpage></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Tiano</surname><given-names>L</given-names></name><name><surname>Belardinelli</surname><given-names>R</given-names></name><name><surname>Carnevali</surname><given-names>P</given-names></name><name><surname>Principi</surname><given-names>F</given-names></name><name><surname>Seddaiu</surname><given-names>G</given-names></name><name><surname>Littarru</surname><given-names>GP</given-names></name><article-title>Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>2249</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehm267</pub-id><pub-id pub-id-type="pmid">17644511</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Bahorun</surname><given-names>T</given-names></name><name><surname>Soobrattee</surname><given-names>MA</given-names></name><name><surname>Luximon-Ramma</surname><given-names>V</given-names></name><name><surname>Aruoma</surname><given-names>OI</given-names></name><article-title>Free radicals and antioxidants in cardiovascular health and disease</article-title><source>Internet J Med Update</source><year>2006</year><volume>1</volume><fpage>25</fpage><lpage>41</lpage></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Molyneux</surname><given-names>SL</given-names></name><name><surname>Young</surname><given-names>JM</given-names></name><name><surname>Florkowski</surname><given-names>CM</given-names></name><name><surname>Lever</surname><given-names>M</given-names></name><name><surname>Georgr</surname><given-names>PM</given-names></name><article-title>Coenzyme Q10: is there a clinical role and a case for measurement?</article-title><source>Clin Biochem Rev</source><year>2008</year><volume>29</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">18787645</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Stocker</surname><given-names>R</given-names></name><name><surname>Bowry</surname><given-names>VW</given-names></name><name><surname>Frei</surname><given-names>B</given-names></name><article-title>Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol</article-title><source>Proc Natl Acad Sci U S A</source><year>1991</year><volume>88</volume><fpage>1646</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.5.1646</pub-id><pub-id pub-id-type="pmid">2000375</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Constantinescu</surname><given-names>A</given-names></name><name><surname>Maguire</surname><given-names>JJ</given-names></name><name><surname>Packer</surname><given-names>L</given-names></name><article-title>Interactions between ubiquinones and vitamins in membranes and cells</article-title><source>Mol Aspects Med</source><year>1994</year><volume>15</volume><fpage>s57</fpage><lpage>s65</lpage><pub-id pub-id-type="pmid">7752845</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Stoyanovsky</surname><given-names>DA</given-names></name><name><surname>Osipov</surname><given-names>AN</given-names></name><name><surname>Quinn</surname><given-names>PJ</given-names></name><name><surname>Kagan</surname><given-names>VE</given-names></name><article-title>Ubiquinone-dependent recycling of vitamin E radicals by superoxide</article-title><source>Arch Biochem Biophys</source><year>1995</year><volume>323</volume><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1006/abbi.1995.9955</pub-id><pub-id pub-id-type="pmid">7487097</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Lass</surname><given-names>A</given-names></name><name><surname>Sohal</surname><given-names>RS</given-names></name><article-title>Electron transport-linked ubiquinone-dependent recycling of &#x003b1;-tocopherol inhibits autooxidation of mitochondrial membranes</article-title><source>Arch Biochem Biophys</source><year>1998</year><volume>352</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1006/abbi.1997.0606</pub-id><pub-id pub-id-type="pmid">9587410</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Schmelzer</surname><given-names>C</given-names></name><name><surname>Lindner</surname><given-names>I</given-names></name><name><surname>Rimbach</surname><given-names>G</given-names></name><name><surname>Niklowitz</surname><given-names>P</given-names></name><name><surname>Menke</surname><given-names>T</given-names></name><name><surname>Doring</surname><given-names>F</given-names></name><article-title>Functions of coenzyme Q10 in inflammation and gene expression</article-title><source>Biofactors</source><year>2008</year><volume>32</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1002/biof.5520320121</pub-id><pub-id pub-id-type="pmid">19096114</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Schmelzer</surname><given-names>C</given-names></name><name><surname>Lorenz</surname><given-names>G</given-names></name><name><surname>Rinbach</surname><given-names>G</given-names></name><name><surname>Doring</surname><given-names>F</given-names></name><article-title>In vitro effects of the reduced form of coenzyme Q(10) on secretion levels of TNF-alpha and Chemokines in response to LPS in the human monocytic cell line THP-1</article-title><source>J Clin Biochem Nutr</source><year>2009</year><volume>44</volume><fpage>62</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.3164/jcbn.08-182</pub-id><pub-id pub-id-type="pmid">19177190</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Eber</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Rodriguez</surname><given-names>Y</given-names></name><name><surname>Levitt</surname><given-names>RC</given-names></name><name><surname>Takacs</surname><given-names>P</given-names></name><name><surname>Candiotti</surname><given-names>KA</given-names></name><article-title>Prophylactic and antinociceptive effects of coenzyme Q10 on diabetic neuropathic pain in a mouse model of type 1 diabetes</article-title><source>Anesthesiology</source><year>2013</year><volume>118</volume><fpage>945</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e3182829b7b</pub-id><pub-id pub-id-type="pmid">23334664</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Pischon</surname><given-names>T</given-names></name><name><surname>Girman</surname><given-names>GJ</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><article-title>Plasma adiponectin levels and risk of myocardial infarction in Men</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1001/jama.291.14.1730</pub-id><pub-id pub-id-type="pmid">15082700</pub-id></mixed-citation></ref></ref-list></back></article>